Navigation Links
PharmaVentures' Client Sanofi Wins Scrip 'Outsourcing Deal of the Year Award'
Date:1/12/2012

OXFORD, English, January 12, 2012 /PRNewswire/ --

PharmaVentures announced today that it was delighted to play an advisory role in the Sanofi - Covance deal which won Scrip's 'Outsourcing Deal of the Year 2011'.

The judges described the deal as 'impressive' as it was "one the largest and most comprehensive R&D alliances in the history of the pharmaceutical and CRO industry".Under the terms of the agreement, Sanofi retains access to some of the capabilities that were divested to Covance as part of a long-term strategic alliance. Covance will provide Sanofi with an up to 10-year sole source relationship for central lab services.

Kevin Bottomley, Head of Transactions at PharmaVentures who was lead advisor to Sanofi on the deal said:  "This is a great recognition for Sanofi as this was a ground-breaking deal which ultimately supports both its overall strategic intent."

Fintan Walton, Chief Executive of PharmaVentures said: "Deal making has become both more complex and more sophisticated. This Scrip Award recognises how PharmaVentures' clients are reaching new heights in deal making. We are delighted to be advisors to this award winning deal."

Over the years PharmaVentures has built considerable experience in the M&A field including divestments of manufacturing and R&D businesses.

Note to Editors

If you wish to write an article, please contact us for any further information you require.

About PharmaVentures

PharmaVentures (http://www.pharmaventures.com) is an international healthcare advisory group providing leadership in all aspects of deals and alliances, from strategy formulations to implementation. The company occupies a special position in the global marketplace because of our track record of successful outcomes, resulting from our unique insight into the world of deal making, our internationally recognised analytical and valuation capabilities, our own proprietary deal making database PharmaDeals®(http://www.pharmadeals.net), containing over 42,000 deal records, and our extensive business relationship network and our outstanding success in M&A transactions.

Our Services Cover:

  • Valuation (for licensing, acquisitions, divestments, fund raising & expert testimonies)
  • Licensing (In and Out licensing)
  • M&A (Companies & Assets)
  • Strategy (commercialisation, deal strategy, due diligence, market entry)
  • Expert Testimony (Patent Infringement, Deal Disagreements, Taxation, Determining Damages)

Now in its 20th year, PharmaVentures is based in Oxford, UK, and employs over 30 people.

PharmaDeals® and PharmaVentures® are registered Trade Marks of PharmaVentures Ltd.

For further information, contact:
Kevin Bottomley
Head of Transactions
+44 1865-332700
Kevin.Bottomley@pharmaventures.com



'/>"/>
SOURCE PharmaVentures Ltd
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. PharmaVentures Appoints Andy Smith as Head of Corporate Finance
2. PharmaVentures Engaged by Astex Therapeutics to Assist in the Divestment of US Facility
3. Matrix Corporate Capital and PharmaVentures Announce the Signing of a Memorandum of Understanding (MOU)
4. PharmaVentures Corporate Advisory Appoints Nikki Watkins as Practice Head, Product & Portfolio Strategy
5. PharmaVentures Assists Helsinn in the Successful Sale of Helsinn Chemicals Ireland to the Medinco C.F.M. Group
6. Merck Engages PharmaVentures to Assist in the Divestment of its Italian Research Centre IRBM
7. Netsmart Clients to Receive Nearly $2 Million in Meaningful Use EHR Incentive Payments
8. AquaStar Holdings, Inc.s Client Receives U.S. Patent 7,708,944 for Portable Capillary Sensor Technology
9. Paul Pospisil Joins Korn/Ferry as Senior Client Partner in Biotechnology and Life Sciences Practice
10. Sermo Announces New Client Center with Advanced Mining and Monitoring of Organic Physician Dialog
11. bj-diagnostik Renforce le Conseil-client Pour les Tests ADN de Fratrie et de Paternit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... ... May 27, 2016 , ... Doctors in Italy, Japan, the UK and the ... associated protein (BAP1) gene and its link to malignant mesothelioma. Surviving Mesothelioma has just ... the full article now. , The studies analyzed for the new report included ...
(Date:5/27/2016)... , May 27, 2016 At present, ... playing in this space know that volatility is what makes ... companies on ActiveWallSt.com: Synta Pharmaceuticals Corp. (NASDAQ: SNTA ... Inc. (NASDAQ: LPTN ), and Heat Biologics Inc. ... access to the technical alerts for these stocks at: ...
(Date:5/26/2016)... Jersey and READING, England ... Indegene ( http://www.indegene.com ), a leading global ... life science, pharmaceutical and healthcare organisations and TranScrip ... innovative scientific support throughout the product lifecycle, today ... the launch of IntraScience.      (Logo: ...
(Date:5/26/2016)... , May 26, 2016 Despite the ... value in this space. Today,s pre-market research on ActiveWallSt.com directs ... Health Inc. (NASDAQ: RDUS ), Cerus Corp. (NASDAQ: ... ARWR ), and Five Prime Therapeutics Inc. (NASDAQ: ... briefings at: http://www.activewallst.com/ On ...
Breaking Biology Technology:
(Date:5/9/2016)... , UAE, May 9, 2016 ... when it comes to expanding freedom for high net ... Even in today,s globally connected world, there is ... conferencing system could ever duplicate sealing your deal with ... obtaining second passports by taking advantage of citizenship via ...
(Date:4/26/2016)... BANGALORE, India and LONDON ... Infosys Finacle, part of EdgeVerve Systems, a ... ), and Onegini today announced a partnership to ... banking solutions.      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ... banks to provide their customers enhanced security to ...
(Date:4/15/2016)... April 15, 2016 Research ... Gait Biometrics Market 2016-2020,"  report to their offering.  ... ) , ,The global gait biometrics market is ... during the period 2016-2020. Gait analysis ... can be used to compute factors that are ...
Breaking Biology News(10 mins):